SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyte immunoglobulin (hIgG) for delaying the onset and progression of autoimmune type 1 diabetes (T1D), today announced that it will present at the 61stAnnual Meeting of the European Association for the Study of Diabetes (EASD) being held September 15 – 19, 2025 at the VIECON - Vienna Congress & Convention Center in Vienna, Austria. The Company will have four oral presentations, as well as an INNODIA-hosted symposium at EASD.

Information on all presentations is below:

Working to Change the Lives of People Impacted​by Type 1 Diabetes Through UniqueDisease-Modifying TherapyPresenter:Alexandra Kropotova, MD, MBA, EVP and Chief Medical OfficerPresentation Date & Time:Monday, September 15, 2025 | 16:40 – 20:00 CESTLocation:Lima Hall

Immunomodulation Without Sustained Lymphodepletion: SAB-142, a Fully HumanAnti-Thymocyte GlobulinSession:Behind the Screens: Adventures in T1D Clinical Trials | Presentation 19Presenter:Alexandra Kropotova, MD, MBA, EVP and Chief Medical OfficerPresentation Date & Time:Tuesday, September 16, 2025 | 10:00 – 11:30 CESTLocation:Mumbai Hall

Mechanism of Action of a Fully Human Anti-Thymocyte Globulin, SAB-142, for the Treatmentof Type 1 DiabetesSession:OP 28 “Guardians of the Islet Galaxy: Protect and Replace” | Presentation 163Presenter:Christoph Bausch, PhD, EVP and Chief Operating OfficerPresentation Date & Time:Thursday, September 18, 2025 | 10:45 – 12:15 CESTLocation:Sofia Hall

Novel Pharmacokinetic Assay for Measuring SAB-142, a Fully Human Anti-Thymocyte GlobulinSession:Clinical Tales from the T1D Trenches | Short Oral Discussion - Event F | Presentation 391Presenter:Eric Sandhurst, PhD, Director of Program ManagementPresentation Date & Time:Thursday, September 18, 2025 | 14:00 – 15:00 CESTLocation:Station 03, Hall C

Specimen Quality for Multicenter Clinical Trials: Comparing Novel Blood Preservation Methods to Cryopreserved PBMCSession:Clinical Tales from the T1D Trenches | Short Oral Discussion - Event F | Presentation 392Presenter:Eric Sandhurst, PhD, Director of Program ManagementPresentation Date & Time:Thursday, September 18, 2025 | 14:00 – 15:00 CESTLocation:Station 03, Hall C

The EASD Annual Meeting is the largest diabetes conference in the world, attracting thousands of delegates. The program showcases the latest results from basic and clinical research.

For more information, visithttps://www.easd.org/annual-meeting/easd-2025/.

INNODIA is an international non-profit organization that stemmed from a European-based public-private partnership co-funded by the European Commission’s Innovative Medicines Initiative (IMI-JU Joint Undertaking), The Hemsley Charitable Trust, Breakthrough T1D, and EFPIA partners. Thanks to this unique private-public interaction, INNODIA has become the largest European Network dedicated to prevent and cure type 1 diabetes and today it is a legal entity that represents the interface between those who want to develop new therapies and those who have the tools and experience to do so.

For more information, visithttps://www.innodia.eu/.

SAB BIO is a clinical-stage biopharmaceutical company focused on developing human, multi-specific, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors.